for males (full criteria)
at Davis, California and other locations
study started
Principal Investigator
by Craig McDonald, MD



The intent of this protocol is to provide continued access to vamorolone for subjects in the United States who Have Completed the VBP15-LTE, VBP15- 004, or VBP15-006 protocols (and are thereby ineligible to enroll in another trial of vamorolone therapy), during the time a new drug application for vamorolone is under preparation and review.

Official Title

An Open-Label, Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy Who Have Completed the Long-Term Extension (VBP15-LTE) or VBP15-004 or VBP15-006 Studies


Vamorolone will be shipped to the subject's family by the study site. The patient will receive standard of care treatment and procedures for management of DMD. Treating Physicians participating in the expanded access program are required to collect and document any physician, patient, or caregiver reported safety events and report to the Sponsor. The subject's dose of vamorolone may be increased or decreased within a range of 2.0 to 6.0 mg/kg/day (only doses of 2 mg/kg, 4 mg/kg and 6 mg/kg are allowed), given once daily. Administration of vamorolone (taken with an 8 ounce (240 ml) glass of full fat milk, or equivalent high-fat food portion) will be unchanged from the VBP15-LTE, VBP15-004, or VBP15-006 studies. In the absence of safety concerns, and while this Expanded Access protocol isactive, vamorolone may be provided indefinitely or until approval, providedthat the Treating Physician and family agrees that continued administrationof vamorolone is in the best interest of the child.


Duchenne Muscular Dystrophy, Vamorolone, VBP-15, DMD, Muscular Dystrophies


You can join if…

Open to males

  • Subject's parent or legal guardian has provided written informed consent/HIPAA authorization
  • Subject has previously completed at a participating US or Canada study site VBP15-LTE up to and including the Month 24 assessments, OR VBP15-004 up to and including the Week 48 assessments, VBP15-006 up to and including the Week 12 assessment
  • Subject and parent/guardian are willing and able to comply with recommended study drug administration plan, and standard of care follow-up and monitoring as recommended by their Treating Physician

You CAN'T join if...

  • Subject had a serious or severe adverse event in study VBP15-LTE or VBP15-004 or VBP15-006 that, in the opinion of the Treating Physician and Sponsor, was probably or definitely related to vamorolone use and precludes safe use of vamorolone for the subject in this expanded access program
  • Subject and/or parent/guardian are unable and/or unwilling to comply with regular medical care and follow-up as recommended by their Treating Physician throughout participation in the VBP15-EAP


  • University of California Davis not accepting new patients
    Davis California 95616 United States
  • Seattle Children's not accepting new patients
    Seattle Washington 98105 United States

Lead Scientist at UC Davis

  • Craig McDonald, MD
    Professor, Physical Medicine and Rehabilitation, School of Medicine. Authored (or co-authored) 244 research publications


accepting new patients
Start Date
Santhera Pharmaceuticals
ReveraGen BioPharma Vamorolone Phase IIa trial in Duchenne Muscular Dystrophy Sign up for this study
Study Type
Expanded Access
Last Updated